Moderna, mRNA

Moderna provided an update on the status of its trial investigating a vaccine candidate for norovirus in a company statement on Monday.
Chairman Larry Ellison highlighted the AI's potential in the development of mRNA-based cancer vaccines. Read more here.
Moderna cut its 2025 sales forecast by $1 billion on Monday, hurt by a slow adoption of its respiratory syncytial virus (RSV) ...
Moderna conducts phase 3 trial for norovirus vaccine as cases rise in the U.S., with results expected in late 2025 or early 2026.
The misery of the common stomach flu may be coming to an end. Pharmaceutical company Moderna has launched a large-scale Phase ...
We recently compiled a list of the These 10 Companies Led Gains on Wednesday. In this article, we are going to take a look at ...
Moderna stock has fallen over the past four years, but shares got a boost on positive comments about AI. Is MRNA stock a buy ...